22 Oct Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development
Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs.
Under the collaboration, Invenra will leverage its proprietary B-Body® Bispecific platform and T-Body™ Trispecific antibody platform to generate novel multispecific antibody formats, while Xcellon Biologics will provide bioconjugation, ADC development, and manufacturing services to create and evaluate multispecific ADC candidates derived from these platforms. The partnership aims to accelerate the translation of bispecific and trispecific ADCs from discovery into preclinical and clinical development.
Invenra’s B-Body® and T-Body™ platforms combine rapid antibody discovery with high developability, streamlining progression from idea to clinic and making them an ideal foundation for efficient ADC development. “Our platforms eliminate lengthy optimization, supporting a seamless path from initial discovery to clinical ADC candidates,” said Bonnie Hammer, Executive VP R&D of Invenra. “This greatly accelerates and de-risks our partners’ ADC programs”.